

## NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE


# **Single Technology Appraisal**

Mirdametinib for treating symptomatic inoperable plexiform neurofibromas in people 2 years and over with neurofibromatosis type 1 ID6618

## **Provisional Stakeholder List**

Provisional Consultees	Provisional Commentators (no right to submit or appeal)
Company	General
SpringWorks Therapeutics	All Wales Therapeutics and Toxicology     Centre
Patient/carer groups	Allied Health Professionals Federation
<ul><li>Brain and Spine Foundation</li><li>Brain Charity</li></ul>	<ul> <li>Board of Community Health Councils in Wales</li> </ul>
Childhood Tumour Trust	British National Formulary
Genetic Alliance UK	Care Quality Commission
Nerve Tumour UK	Department of Health - Northern Ireland
Neurological Alliance	Healthcare Improvement Scotland
South Asian Health Foundation	Medicines and Healthcare products
Specialised Healthcare Alliance	Regulatory Agency
	National Association of Primary Care
Healthcare professional groups	National Pharmacy Association
Association of Anaesthetists	Neurological Alliance of Scotland
Association of British Neurologists	NHS Confederation
Association of Genetic Nurses &	<ul> <li>NHS Wales Joint Commissioning</li> </ul>
Counsellors	Committee
<ul> <li>Association of Surgeons of Great</li> </ul>	<ul> <li>Scottish Medicines Consortium</li> </ul>
Britain and Ireland	<ul> <li>Wales Neurological Alliance</li> </ul>
British Geriatrics Society	<ul> <li>Welsh Government</li> </ul>
British Neuropathological Society	
British Paediatric Neurology	Possible comparator companies
Association	<ul> <li>AstraZeneca (selumetinib)</li> </ul>
British Society for Gene and Cell  The graph.	Delevent recession maying
Therapy	Relevant research groups
British Society for Genetic Medicine     Institute of Neurology	Brain Research UK     Cookrana Cyclia Fibracia & Constin
Institute of Neurology     Primary Care and Community	<ul> <li>Cochrane Cystic Fibrosis &amp; Genetic Disorders Group</li> </ul>
<ul> <li>Primary Care and Community Neurology Society</li> </ul>	Genomics England
Royal College of Anaesthetists	MRC Clinical Trials Unit
Royal College of General Practitioners	National Hospital for Neurology and
Royal College of Nursing	National Institute for Health Research
Royal College of Natishing     Royal College of Paediatrics & Child	- Madorial module for Health Mesodich
Health	Associated Public Health groups
Royal College of Pathologists	Public Health Wales

Provisional stakeholder list for the evaluation of mirdametinib for treating symptomatic inoperable plexiform neurofibromas in people 2 years and over with neurofibromatosis type 1 ID6618 Issue date: October 2025



Provisional Consultees	Provisional Commentators (no right to submit or appeal)
<ul> <li>Royal College of Physicians</li> <li>Royal College of Surgeons</li> <li>Royal Pharmaceutical Society</li> <li>Royal Society of Medicine therapy</li> <li>UK Clinical Pharmacy Association</li> </ul>	UK Health Security Agency
<ul> <li>Others</li> <li>Department of Health and Social Care</li> <li>Guy's and St Thomas' NHS     Foundation Trust</li> <li>Manchester University NHS     Foundation Trust</li> <li>NHS England</li> </ul>	

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

#### **Definitions:**


Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.

#### Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).



### Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.